Calidi Biotherapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $45.0K | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $9.7M | $8.9M | $13.0M | $7.3M | — |
| SG&A Expense | — | $10.5M | $12.9M | $16.0M | $15.9M | — |
| Operating Income | — | $-20.2M | $-21.8M | $-29.0M | $-23.1M | — |
| Operating Margin | — | — | — | — | -51,395.6% | — |
| Interest Expense | — | $100.0K | $700.0K | $1.1M | $200.0K | — |
| Pretax Income | — | $-20.0M | $-22.2M | $-29.2M | $-25.4M | — |
| Income Tax Expense | — | $15.0K | $14.0K | $16.0K | $11.0K | — |
| Net Income | — | $-19.9M | $-22.1M | $-29.2M | $-25.4M | — |
| Net Margin | — | — | — | — | -56,504.4% | — |
| EPS (Basic) | — | $-5.95 | $-35.70 | $-3.47 | $0.60 | — |
| EPS (Diluted) | — | $-5.95 | $-35.70 | $-3.47 | $0.60 | — |
| Shares Outstanding (Basic) | 10.9M | 4.3K | 8.0M | 8.4M | 42.5M | 115.0M |
| Shares Outstanding (Diluted) | 10.9M | 4.3K | 8.0M | 8.4M | 42.5M | 115.0M |
| Dividends Per Share | — | — | — | — | — | — |